SCHEMBL323140

SCHEMBL323140

O=C(OCc1cc(F)ccc1F)N1C=Cc2ccccc2C1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.42
MMP12 P39900 2/20 0.42
MMP1 P03956 1/20 0.42
MMP9 P14780 1/20 0.42
PTGDR2 Q9Y5Y4 8/20 0.37
XIAP P98170 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
TAS1R2 Q8TE23 1/20 0.35
HDAC3 O15379 1/20 0.34
THRB P10828 1/20 0.34
HSD17B3 P37058 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
TACR1 P25103 2/20 0.33
ALKBH1 Q13686 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323401 0.91 BCL9 (0.40) PTGDR2TAS1R3TAS1R1TAS1R2HDAC3
SCHEMBL323904 0.90 ALDH1A1 (0.37) MMP2MMP12MMP1MMP9PTGDR2
SCHEMBL324441 0.90 HSD17B3 (0.43) PTGDR2XIAPHDAC3HSD17B3
SCHEMBL323574 0.88 GRIN2B (0.41) MMP2MMP12MMP1MMP9
SCHEMBL324380 0.84 P2RX4 (0.42) MMP2MMP12MMP1MMP9PTGDR2
SCHEMBL323355 0.84 HCAR2 (0.43) MMP2MMP12MMP1MMP9PTGDR2
SCHEMBL324997 0.82 F13A1 (0.39) MMP2MMP12MMP1MMP9PTGDR2
SCHEMBL325479 0.82 RECQL (0.41) PTGDR2SIGMAR1
SCHEMBL323819 0.81 MMP1 (0.39) MMP2MMP12MMP1MMP9PTGDR2
SCHEMBL325232 0.81 HSD17B3 (0.46) PTGDR2XIAPTAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9255090-B2 Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-09 US disclosed
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 US disclosed
EP-2794563-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2014-10-29 EP disclosed
WO-2013093842-A1 HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2013-06-27 WO disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252036-A1 Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators PTGDR, PTGER1, PTGDR2 MMP2 2839/4885MMP12 1919/4885MMP1 3636/4885
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 MMP2 3105/4885MMP12 2464/4885MMP1 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.